TriangleZanzalintinib (NCT07283731)
Zanzalintinib trial for Phase 2 (NCT07283731). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic undifferentiated pleomorphic sarcoma, myxofibrosarcoma, high-grade pleomorphic sarcoma, or high-grade undifferentiated sarcoma. Prior checkpoint inhibitors or zanzalintinib are excluded.
The idea: oral zanzalintinib blocks signals involved in tumor growth and blood-vessel formation. Intravenous pembrolizumab removes an immune-system brake. Researchers test the combination's safety and how long disease stays controlled. Measurable disease is required, along with consent to a companion biopsy study. Brain-metastasis criteria need confirmation.
This phase 2 study plans 20 patients. Michael Nakazawa leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.